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We report the case of an otherwise healthy 64-year-old female who developed cardiopulmonary arrest
after the administration of pilsicainide for treatment of paroxysmal atrial ﬁbrillation. She had had an
episode of paroxysmal atrial ﬁbrillation, but no liver dysfunction, renal dysfunction, or echocardiographic
abnormality before her admission. On the day of admission and the following day, 50 mg of pilsicainide
was administered intravenously over 10 min (total 100 mg). Shortly after the second injection, she
developed marked bradycardia and hypotension and eventually fell into a state of pulseless electrical
activity. Immediate cardiopulmonary resuscitation was started. Although application of a temporary
pacemaker restored her heart rate, echocardiography revealed no left ventricular contraction. We started
percutaneous cardiopulmonary support (PCPS) and intra-aortic balloon pumping (IABP). Her cardiac
contraction gradually recovered and returned to completely normality 3 days after the onset. The patient
was discharged in an ambulatory condition.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Pilsicainide is one of the most common antiarrhythmic agents
for the treatment of paroxysmal atrial ﬁbrillation (pAF). It has a
pure sodium channel-blocking action with a slow recovery time
constant [1–3], and exerts its antiarrhythmic action by suppressing
the maximum depolarization rate of the cell membrane action
potential, resulting in a decrease in the impulse conduction rate.
Since pilsicainide is considered relatively safe and potent for
rhythm conversion and maintenance of sinus rhythm in patients
with pAF [4], it has been widely used in Japan and is recognized as
the ﬁrst-line drug for pAF in the Japanese Circulation Society
Guidelines for Drug Treatment of Arrhythmias (2009). Here we
report a very rare case where pilsicainide induced marked nega-
tive inotropic and chronotropic effects, despite the absence of any
detectable underlying heart disease.t Rhythm Society. Published by Els
+81 92 642 5989.
).2. Case report
A 64-year-old woman was transferred to our hospital by
ambulance with strong palpitations. She was 150 cm in height
and weighed 55 kg. She was fully conscious and there were no
abnormal neurological ﬁndings. Blood pressure was 131/93 mmHg
and her pulse was irregular, with a mean rate of 140 bpm (Fig. 1A).
Percutaneous oxygen saturation (SpO2) under room air was 96%.
She had a history of pAF, which had been treated at another
hospital. On that occasion, 100 mg of pilsicainide was administered
orally and she suffered cardiac arrest. As the patient did not
remember this event on her current admission, we started our
treatment without having this information.
The supervising physician administered 0.5 mg of propranolol
and 50 mg of pilsicainide intravenously for about 8 min around
midnight, but the AF persisted until the next morning. Her blood
test showed no liver or renal dysfunction and her echocardiogra-
phy study showed normal cardiac function (Table 1). At 9:00 am
the next morning, we added 0.25 mg of intravenous digoxin, and
another 50 mg of pilsicainide dissolved in 100 ml of normal saline
was administered from 12:08 pm over 10 min (Fig. 2A). Mild
bradycardia developed during administration (Fig. 2B). Just after
the completion of the injection, at 12:22 pm, she fell into a state ofevier B.V. All rights reserved.
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Fig. 1. 12-lead ECG around the administration of pilsicainide. (A) 12-lead ECG before the ﬁrst administration of pilsicainide. (B) 12-lead ECG after the second administration
of pilsicainide.
Table 1
Results of ultrasound cardiography.
1 day 2
days
3
days
4
days
Before
administration
After
administration
LVDd
(mm)
41 44 49 36 41
LVDs
(mm)
24 43 42 24 23
EF (%) 74 3.6 31 64 76
LVDd, left ventricular diastolic diameter; LVDs, left ventricular systolic diameter;
and EF, ejection fraction.
Fig. 2. ECG monitoring around the second administration of pilsicainide. (A) ECG
monitoring before the administration; atrial ﬁbrillation with rapid ventricular
response. (B) ECG monitoring during the administration; atrial ﬁbrillation with
slow ventricular response. (C) ECG monitoring after the administration; long sinus
arrest.
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cardiopulmonary resuscitation. As the patient's circulatory status
did not improve after the intravenous administration of 1 mg of
epinephrine (Fig. 1B), we inserted a temporary pacemaker at
13:25 pm. The stimulation threshold of the temporary pacemaker
was below 0.3 V. As profound hypotension remained even with
these efforts, while no actual cardiac contraction was observed on
the echocardiogram (left ventricular ejection fraction 3.6%,
Table 1), we decided to use percutaneous cardio-pulmonary
support (PCPS) and intra-aortic balloon pumping (IABP), which
were able to stabilize her hemodynamic condition. The blood
concentration of pilsicainide at this point, approximately 3 h after
administration, was within the safe and effective range (0.39 mg/
dl). The left ventricular ejection fraction recovered to 31% by the
second day, and as it was almost normalized on the third day(64%), PCPS and IABP were terminated. On the fourth day, the
patient was well enough to be extubated (Table 1).
MRI, including delayed enhancement, revealed no cardiac
abnormalities on the tenth day, and cardiac catheterization on
the fourteenth day showed no signiﬁcant coronary lesions. Sinus
node function and atrioventricular conduction were also within
normal limits on electrophysiological testing. In addition, no
signiﬁcant ﬁnding was noted in her myocardial biopsy specimen
and no variant was found in the cardiac sodium channel genes,
SCN5A and KCNH2. Rehabilitation was carried out for 2 months,
M. Yoshida et al. / Journal of Arrhythmia 30 (2014) 68–7070and she was discharged in ambulatory condition. AF did not recur
during this period of admission. The prescribed drug at the time of
discharge was only warfarin, and we recommended that pulmon-
ary vein isolation should be performed when the next attack of AF
occurred.3. Discussion
We report the case of a patient with pAF who had no speciﬁc
medical history, but showed catastrophic negative inotropic and
chronotropic effects in response to pilsicainide. Although the
negative inotropic effect of pilsicainide is believed to be relatively
weak, there are some reports of a signiﬁcant increase in pulmon-
ary artery wedge pressure after its administration [5,6]. It has also
been reported that the administration of large doses (3–6 mg/kg)
of pilsicainide to anesthetized dogs lowered blood pressure and
heart rate in a dose-dependent manner [7]. The concentration of
serum pilsicainide in these dogs was far higher than in our case.
Cardiac suppression has been observed in patients who attempted
suicide who took massive doses of pilsicainide and atenolol. In
such cases, however, the separate effect of pilsicainide was unclear
[8]. In another suicide attempt, where approximately 2000 mg of
pilsicainide was taken, severe pump failure occurred [9]. Though
the patient's hemodynamic state in that case was supported by a
combination of IABP and PCPS, as in our patient, the hemodynamic
progression appears to have been milder, taking into account that
a far larger dose of pilsicainide was administered.
It is recommended that pilsicainide be administered over
10 min, with 1.0 mg/kg being the maximum daily dosage allowed.
However, a single oral dose of pilsicainide has been shown to be
effective, feasible and safe, and the single dose is always from 100
to 150 mg [4,10]. Both the time to maximum drug concentration
(Tmax) and the half-life of pilsicainide are approximately 3 h.
Though the half-life of pilsicainide is prolonged in cases of renal
dysfunction, since it is a renally excreted drug [11], renal dysfunc-
tion was not observed in our patient. In fact, given that the blood
concentration of pilsicainide 3 h after re-administration in our
case was 0.39 mg/ml, we do not consider that the pilsicainide
concentration was sufﬁciently high to induce the serious cardiac
suppression [12]. In addition, we could not detect any sodium
channel abnormalities. An effect of digoxin was considered as one
of the possible causes of bradycardia. However, because the heart
rate dropped within a short time after pilsicainide administration,
while about 3 h had passed since digoxin had been injected,
digoxin may not have played an important role in the bradycardia.
Some negative inotropic effects of propranolol might have
been involved, as the pilsicainide was administered about 12 h
after the injection of propranolol. However, since the half-life ofpropranolol is 2.3 h, we consider that the role of the injected
propranolol would have been limited if any.
Thus, there is no clear answer at the present time as to why this
amount of pilsicainide caused such a fatal inhibitory effect on our
patient's seemingly normal heart. However, we should recognize
that this type of totally unexplained serious adverse effect can
happen totally unexpectedly, even in patients who have appar-
ently normal cardiac function.Disclosures
This study involved no ﬁnancial support or off-label or inves-
tigational drug use. The patient gave informed consent for the
publication of the clinical data and her anonymity has been
preserved.Conﬂict of interest
None.
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